Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Canada Postdoctoral Research Award (CPRA) program

Direct Payment

$140,000.00

Tracking the Evolution of the Integrated SIV Reservoir During Antiretroviral Therapy

EF 2025-26

Résumé
HIV can be controlled with daily drugs, but it is not cured. HIV is a retrovirus: it copies itself into DNA and hides inside long-lived immune cells. These hidden cells form a "reservoir." Drugs stop new infections, but they do not remove this reservoir. If treatment stops, the virus often returns. Many people take HIV medicines for decades, with side effects and daily burden, and staying on treatment is hardest for people who face barriers to care. My project asks: why do some hidden infected cells multiply during treatment and keep the virus alive? One clue is the spot in the host's DNA, the human cell's own genetic material, where the virus inserts its copy. This spot is called the "integration site," and some of these sites may help groups of infected cells grow and allow the virus to continue to reproduce. By learning which DNA spots and body signals allow this growth, we can better find these cells and remove them. To study this safely, I will use SIV, the monkey version of HIV. I will follow the same SIV-infected monkeys for six years during treatment. From blood samples collected over time from these monkeys, large datasets have already been generated measuring where the virus sits in DNA, which genes are active in individual infected cells, and proteins and small molecules that show how the body is responding. I will process these large datasets with specialized computer analysis in order to guide development of therapies that finds the virus and removes it permanently. The goal is to learn which infected cells persist during treatment and why. The results can point to targets for cures that either wake and remove those cells or keep the virus locked down. They can guide vaccines and treatments, support clinical trials with better reservoir tracking, and help health systems use therapies more effectively. In plain terms: reduce lifelong treatment, lower the risk of recurrence, and improve care - especially for communities facing barriers.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
537115
Name
Mostefai Fatima
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Tracking the Evolution of the Integrated SIV Reservoir During Antiretroviral Therapy
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Bioinformatics; Clonal Expansion; Genomics; Hiv/Siv Reservoir; Integration Site Mapping; Longitudinal Cohort (Art); Population Genetics & Machine Learning; Proteomics/Metabolomics; Single-Cell Atac-Seq; Single-Cell Rna-Seq
Abstract
HIV can be controlled with daily drugs, but it is not cured. HIV is a retrovirus: it copies itself into DNA and hides inside long-lived immune cells. These hidden cells form a "reservoir." Drugs stop new infections, but they do not remove this reservoir. If treatment stops, the virus often returns. Many people take HIV medicines for decades, with side effects and daily burden, and staying on treatment is hardest for people who face barriers to care. My project asks: why do some hidden infected cells multiply during treatment and keep the virus alive? One clue is the spot in the host's DNA, the human cell's own genetic material, where the virus inserts its copy. This spot is called the "integration site," and some of these sites may help groups of infected cells grow and allow the virus to continue to reproduce. By learning which DNA spots and body signals allow this growth, we can better find these cells and remove them. To study this safely, I will use SIV, the monkey version of HIV. I will follow the same SIV-infected monkeys for six years during treatment. From blood samples collected over time from these monkeys, large datasets have already been generated measuring where the virus sits in DNA, which genes are active in individual infected cells, and proteins and small molecules that show how the body is responding. I will process these large datasets with specialized computer analysis in order to guide development of therapies that finds the virus and removes it permanently. The goal is to learn which infected cells persist during treatment and why. The results can point to targets for cures that either wake and remove those cells or keep the virus locked down. They can guide vaccines and treatments, support clinical trials with better reservoir tracking, and help health systems use therapies more effectively. In plain terms: reduce lifelong treatment, lower the risk of recurrence, and improve care - especially for communities facing barriers.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mostefai, Fatima
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~